Novartis Hopes Eye Drug Beovu Bounces Back After New Approval
Gets EU Okay For Diabetic Macular Edema
Having struggled to allay safety concerns for its use in wet age-related macular degeneration, the Swiss major has faith Beovu's efficacy and less frequent dosing will prove more than a match for established DME rival Eylea and newcomer Vabysmo.
You may also be interested in...
Stock Watch: Regeneron’s Constellation of Ophthalmic Competition
The accepted commercial dynamics of a competitive indication in older patients can be disrupted by new entrants with improved profiles, lower priced biosimilar competition and (soon) Medicare price negotiations.
Keeping Track: GSK’s Priorix Makes Three Novel US FDA CBER Approvals In 2022; Two CV Drugs Among Recent NDAs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Shilpa Medicare’s Plan For Eylea Biosimilar Spells Ambition, But Path Not Easy
Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead